Vestal Point Capital’s MoonLake Immunotherapeutics MLTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$6.14M Buy
+525,000
New +$8.58M 0.16% 48
2025
Q3
– Sell
-550,000
Closed -$26M – 89
2025
Q2
$26M Buy
550,000
+350,000
+175% +$14.3M 1.37% 24
2025
Q1
$7.81M Buy
+200,000
New +$8.62M 0.56% 39

Other funds holding MLTX

Vestal Point Capital's MLTX Position: Q3 2026 in Review

Vestal Point Capital opened a new position in MoonLake Immunotherapeutics (MLTX) in Q3 2026: 525,000 shares worth $6.14M. The stake represents 0.16% of the portfolio and ranks #48 among its holdings. This is a return to the name: Vestal Point Capital previously reported a position in MLTX as recently as Q2 2025.

Vestal Point Capital first reported a position in MLTX in Q1 2025 and has held it in 3 quarters since. The position peaked at $26M in Q2 2025. 170 funds tracked by Wall St. Rank hold MLTX as of Q3 2026.

  • Vestal Point Capital held 525,000 shares of MoonLake Immunotherapeutics worth $6.14M as of Q3 2026.
  • MoonLake Immunotherapeutics was a new Vestal Point Capital position in Q3 2026.
  • MoonLake Immunotherapeutics made up 0.16% of Vestal Point Capital's portfolio in Q3 2026, its #48 holding.
  • Vestal Point Capital first reported a position in MoonLake Immunotherapeutics in Q1 2025 and has held it in 3 quarters since.
  • Vestal Point Capital's MoonLake Immunotherapeutics position peaked at $26M in Q2 2025.
  • 170 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2026.

Based on Vestal Point Capital's 13F filing for Q3 2026, filed 16 Nov 2026.